1. Home
  2. HAIN vs BMEA Comparison

HAIN vs BMEA Comparison

Compare HAIN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hain Celestial Group Inc. (The)

HAIN

Hain Celestial Group Inc. (The)

HOLD

Current Price

$0.80

Market Cap

95.1M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.34

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAIN
BMEA
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.1M
90.5M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
HAIN
BMEA
Price
$0.80
$1.34
Analyst Decision
Hold
Strong Buy
Analyst Count
10
7
Target Price
$2.64
$8.71
AVG Volume (30 Days)
2.3M
989.2K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,457,769,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.87
52 Week High
$4.84
$3.08

Technical Indicators

Market Signals
Indicator
HAIN
BMEA
Relative Strength Index (RSI) 34.38 52.41
Support Level N/A $1.24
Resistance Level $1.23 $1.41
Average True Range (ATR) 0.09 0.10
MACD -0.02 0.02
Stochastic Oscillator 14.22 54.72

Price Performance

Historical Comparison
HAIN
BMEA

About HAIN Hain Celestial Group Inc. (The)

The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: